Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA Waxman/Hatch Plan Would Use Bonds To Protect 180-Day Exclusivity

Executive Summary

The Generic Pharmaceutical Association is proposing to change the Waxman/Hatch patent challenge process to use bonds posted by brand name companies as a substitute for market exclusivity to provide an incentive for generic companies.
Advertisement

Related Content

McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval
McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval
FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First
Par 7.5 Mg Buspirone Aims To Capture Portion of 15 Mg Split-Tablet Market
"First To File" Policy Increases Generics Qualifying For 180-Day Exclusivity
Barr Fluoxetine Will Have Two Months Exclusivity Under "Worst Case"
ANDA 30-Month Stay Of Approval Does Not Apply If Patent Case Is Settled
ANDA 30-Month Stay Of Approval Does Not Apply If Patent Case Is Settled
Advertisement
UsernamePublicRestriction

Register

PS037659

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel